ISSN (Print) - 0012-9976 | ISSN (Online) - 2349-8846

A GNooraniSubscribe to A GNoorani

Terrorism and Law of Evidence

extend help to only those units which agree to scrap their overaged capacity and procure modern vessels. Who's Ailing? IT is not surprising that the Organisation of Pharmaceutical Producers of India (OPPI) should have focused so much attention on the new drug policy at its 21st annual general meeting. For after all the industry has had a major say in the framing of the policy, notwithstanding the pro-consumer frills. OPPI president C M Hattangadi has chosen to describe the policy as a silver lining, but it is hard to see what were the "dark clouds that overcast the industry" last year that he talks about. In fact, all in all the industry has had a very satisfactory year. While profit margins may have fallen in- finitesimally, most of the big units have continued to do very well. Share prices are evidence of this. The RBI share price index 278.8, or nearly 31 per cent, between
Back to Top